13F-HR filed by Kynam Capital Management, LP
Kynam Capital Management, LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 24 holding rows worth $902,614,125.
- Accession
- 0001085146-24-001322
- Filer
- CIK 1907884
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 24 entries on the cover page, a total value of $902,614,125 stated on the cover page (in dollars after the unit check, H1), rows summing to $902,614,125 with VALUE read as dollars as filed, 13F file number 028-21939. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NATERA INC COM | 632307104 | Stock | 2,400,000 | $150,336,000 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 5,660,000 | $122,312,600 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 3,005,904 | $119,214,153 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 1,002,407 | $62,951,160 | dollars as filed | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 3,650,339 | $56,142,214 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 2,004,875 | $45,971,784 | dollars as filed | |
| IMMUNOGEN INC | 45253H101 | COMMON STOCK | 1,422,503 | $42,177,214 | dollars as filed | |
| MORPHOSYS AG | 617760202 | ADR | 4,234,685 | $41,923,382 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 5,854,766 | $34,426,024 | dollars as filed | |
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 2,698,324 | $32,460,838 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 4,600,000 | $27,554,000 | dollars as filed | |
| 2SEVENTY BIO INC COMMON STOCK | 901384107 | Stock | 5,953,825 | $25,422,833 | dollars as filed | |
| DYNAVAX TECHNOLOGIES CORP | 268158201 | COM NEW | 1,514,383 | $21,171,074 | dollars as filed | |
| WAVE LIFE SCIENCES LTD SHS | Y95308105 | Stock | 3,932,082 | $19,857,014 | dollars as filed | |
| CORCEPT THERAPEUTICS INC | 218352102 | COM | 585,900 | $19,030,032 | dollars as filed | put |
| TRAVERE THERAPEUTICS INC | 89422G107 | COM | 2,000,000 | $17,980,000 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 607,915 | $13,240,389 | dollars as filed | |
| AMARIN CORP PLC | 023111206 | SPONS ADR NEW | 12,022,957 | $10,459,973 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 1,200,000 | $8,952,000 | dollars as filed | |
| SUTRO BIOPHARMA INC | 869367102 | COM | 2,001,727 | $8,587,409 | dollars as filed | |
| BURNING ROCK BIOTECH LTD | 12233L107 | SPONSORED ADS | 8,694,426 | $8,085,816 | dollars as filed | |
| CARIBOU BIOSCIENCES INC COM | 142038108 | Stock | 1,068,527 | $6,122,660 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 340,190 | $4,711,632 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 442,704 | $3,523,924 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001085146-24-001322 | this filing | 2024-02-14 | acceptance time not in the bulk data set |